Skip to main content

Advertisement

Table 5 Matches included in base case analysis

From: The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

ID Match 1 Match 2 Drug 1 Drug 2 PFS 1a PFS 2a HRb
Within white network
 1 Hou et al. [73] Lacy et al. [74] dex + len dex + pom 8.3 4.8 0.58
Within black network
 2 Fukushima et al. [72] Terpos et al. [78] bor + dex dex + thal 16.8 8 0.48
 3 Pantani et al. [76] Terpos et al. [78] bor + dex dex + thal 8.7 8 0.92
Connecting both networks
 4 Hou et al. [73] Richardson et al. [77] dex + len bor + dex + pan 8.3 5.4 0.65
 5 Lacy et al. [74] Richardson et al. [77] dex + pom bor + dex + pan 4.8 5.4 1.13
 6 Oehrlein et al. [75] Pantani et al. [76] dex + len bor + dex 11.6 8.7 0.75
 7 Oehrlein et al. [75] Terpos et al. [78] dex + len dex + thal 11.6 8 0.69
 8 Fukushima et al. [72] Oehrlein et al. [75] bor + dex dex + len 16.8 11.6 0.69
  1. bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal thalidomide, vor vorinostat, HR hazard ratio, PFS progression free survival
  2. amedian
  3. bestimated from median PFS assuming exponential survival